CoChat

A Perspective on the Development of c-Jun N-terminal Kinase Inhibitors as Therapeutics for Alzheimer’s Disease: Investigating Structure through Docking Studies

Open access
Cho, Hyunwook, Hah, Jung-Mi · 2021 · Biomedicines

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

c-Jun N-terminal kinase (JNK) plays an important role in cell death caused by various stimuli. Because the isoform JNK3 is mainly expressed in the brain, it is believed to play a pivotal role in various neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD), which still lack plausible therapeutics. To develop a novel and selective JNK3 inhibitor, we conducted a decadal review (2011 to 2021) of published articles on JNK inhibitors, particularly those focusing on a structural perspective and docking insights. We observed the structures of three isoforms of JNK, namely holo-proteins and co-crystal structures, with JNK3 inhibitors and summarized the significant structural aspects of selective JNK3 inhibitors as AD therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biomedicines9101431

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Overall JNK pathway from stress to apoptosis.
Figure 1 Overall JNK pathway from stress to apoptosis.CC BY · PubMed Central
Figure 2 The role of JNK3 in the three pathological pathways of AD.
Figure 2 The role of JNK3 in the three pathological pathways of AD.CC BY · PubMed Central
Figure 3 Chemical structures and activities of three representative pan-JNK inhibitors currently under development.
Figure 3 Chemical structures and activities of three representative pan-JNK inhibitors currently under development.CC BY · PubMed Central
Figure 4 Chemical structures and activities of four JNK inhibitors with isoform selectivity that are currently under development.
Figure 4 Chemical structures and activities of four JNK inhibitors with isoform selectivity that are currently under development.CC BY · PubMed Central
Figure 5 Superimposition of six crystal structures of JNK1 (PDB ID: 3PZE [26], 2XRW [27], 4QTD [28], 3ELJ [29], 4AWI [30], and 4L7F [31]) by pulling out the top six structures according to their resolution. The ligand is compound 3 docked into JNK3 (PDB 4WHZ [22]). Residue Met108 is shown in grey.
Figure 5 Superimposition of six crystal structures of JNK1 (PDB ID: 3PZE [26], 2XRW [27], 4QTD [28], 3ELJ [29], 4AWI [30], and 4L7F [31]) by pulling out the top six structures according to their resolution. The ligand is compound 3 docked into JNK3 (PDB 4WHZ [22]). Residue Met108 is shown in grey.CC BY · PubMed Central
Figure 6 Superimposition of the crystal structures of JNK2 (PDB ID: 3E7O [32], 7CML [33], and 3NPC [34]), of which only three are published. The ligand is compound 3 docked into JNK3 (PDB 4WHZ [22]). Residue Met108 is shown in grey.
Figure 6 Superimposition of the crystal structures of JNK2 (PDB ID: 3E7O [32], 7CML [33], and 3NPC [34]), of which only three are published. The ligand is compound 3 docked into JNK3 (PDB 4WHZ [22]). Residue Met108 is shown in grey.CC BY · PubMed Central
Figure 7 Superimposition of six co-crystals of JNK3 selected according to resolution (PDB ID: 4WHZ [22], 4W4W [35], 3OY1 [25], 7KSI [23], 6EMH [36], and 6EQ9 [36]). Compound 3 is docked into the active site of JNK3 (PDB ID: 4WHZ [22]). Residue Met146 is shown in grey.
Figure 7 Superimposition of six co-crystals of JNK3 selected according to resolution (PDB ID: 4WHZ [22], 4W4W [35], 3OY1 [25], 7KSI [23], 6EMH [36], and 6EQ9 [36]). Compound 3 is docked into the active site of JNK3 (PDB ID: 4WHZ [22]). Residue Met146 is shown in grey.CC BY · PubMed Central
Figure 8 (a) Leu144 residue in the crystal structure of JNK3 co-crystalized with compound 4 (PDB ID: 3OY1 [25]), and (b) superimposition of the Ile106 residue in the crystal structure of JNK1 (PDB ID: 3PZE [26]) and compound 4 co-crystalized with JNK3.
Figure 8 (a) Leu144 residue in the crystal structure of JNK3 co-crystalized with compound 4 (PDB ID: 3OY1 [25]), and (b) superimposition of the Ile106 residue in the crystal structure of JNK1 (PDB ID: 3PZE [26]) and compound 4 co-crystalized with JNK3.CC BY · PubMed Central
Figure 9 (a) Crystal structure of JNK3 bound to compound 1 (PDB ID: 4WHZ [22]). (b) Protein surface of the hydrophobic pocket is shown in the same JNK3 co-crystal. Residues that interact with compound 1 and comprise selectivity pocket are emphasized in the thin tube.
Figure 9 (a) Crystal structure of JNK3 bound to compound 1 (PDB ID: 4WHZ [22]). (b) Protein surface of the hydrophobic pocket is shown in the same JNK3 co-crystal. Residues that interact with compound 1 and comprise selectivity pocket are emphasized in the thin tube.CC BY · PubMed Central
Figure 10 (a) Crystal structure of JNK3 bound to compound 2 (PDB ID: 7KSK [23]) (b) Protein surface of the hydrophobic pocket is shown at the same co-crystal. Residues that interact with compound 2 and comprise selectivity pocket are emphasized in thin tube.
Figure 10 (a) Crystal structure of JNK3 bound to compound 2 (PDB ID: 7KSK [23]) (b) Protein surface of the hydrophobic pocket is shown at the same co-crystal. Residues that interact with compound 2 and comprise selectivity pocket are emphasized in thin tube.CC BY · PubMed Central
Figure 11 (a) Binding mode of compound 3 docked into the structure of JNK3 (PDB ID: 4WHZ [22]). (b) Surface of the hydrophobic pocket in active site is shown at the same docking structure of compound 3. Residues that interact with compound 3 and comprise the selectivity pocket are emphasized in the thin tube.
Figure 11 (a) Binding mode of compound 3 docked into the structure of JNK3 (PDB ID: 4WHZ [22]). (b) Surface of the hydrophobic pocket in active site is shown at the same docking structure of compound 3. Residues that interact with compound 3 and comprise the selectivity pocket are emphasized in the thin tube.CC BY · PubMed Central
Figure 12 (a) Binding mode of compound 4 co-crystallized with JNK3 (PDB ID: 3OY1 [25]). (b) Surface of the selectivity pocket in active site is shown in the same co-crystal. Residues that interact with compound 4 and comprise selectivity pocket are emphasized in the thin tube.
Figure 12 (a) Binding mode of compound 4 co-crystallized with JNK3 (PDB ID: 3OY1 [25]). (b) Surface of the selectivity pocket in active site is shown in the same co-crystal. Residues that interact with compound 4 and comprise selectivity pocket are emphasized in the thin tube.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 28

Metadata

Authors
Cho, H., & Hah, J.-M.
Affiliations
Hanyang University (KR)
Corresponding author
Hah, Jung-Mi
Venue
Biomedicines
Publisher
MDPI AG
Published
2021-10-09
Volume
9
Issue
10
Pages
1431
ISSN
2227-9059 (ISSN-L)
OpenAlex
W3205457107
Cited by
27
References
35
Citations by year
2026: 4 · 2025: 4 · 2024: 10 · 2023: 5 · 2022: 4
FWCI
0.63
Type
journal article
Language
en
Open access
Locations
  • Biomedicines (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Research Foundation of Korea (NRF-2020R1A6A1A03042854, NRF-2021R1A2C2007159)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
c-Jun N-terminal kinase, JNK3 inhibitors, Alzheimer's disease, Parkinson's disease, structure-based drug design, molecular docking, JNK isoforms, co-crystal structure, neurodegenerative diseases, selective kinase inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Perspective on the Development of c-Jun N-terminal Kinase Inhibitors as Therapeutics for Alzheimer’s Disease: Investigating Structure through Docking Studies. https://app.cochat.ai/papers/10.3390/biomedicines9101431
The paper
Cho, H., & Hah, J.-M. (2021). A Perspective on the Development of c-Jun N-terminal Kinase Inhibitors as Therapeutics for Alzheimer’s Disease: Investigating Structure through Docking Studies. Biomedicines. https://doi.org/10.3390/biomedicines9101431

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.